Last reviewed · How we verify
Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC
A single-arm, phase II study for patients with detectable HPV CtDNA at 12 weeks or longer after completion of definitive therapy for non-metastatic, HPV+ squamous cell carcinoma.
Details
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | PHASE2 |
| Status | WITHDRAWN |
| Start date | Thu May 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Aug 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Squamous Cell Carcinoma
Interventions
- Atezolizumab
- Talazoparib